Photodynamic Therapies (PDT) to treat glioblastoma (GBM)
Synaps aims to enhance photodynamic therapies applied to the treatment of glioblastoma, a very agressive brain cancer type, still incurable today.
With a rising incidence up to 5 new cases each year per 100 000 people, glioblastoma is a main cause of death by cancer among the young adults population.
Glioblastoma is still an incurable and a very agressive brain cancer, whose median survival is less than 18 months.
Photodynamic therapy (PDT) to complete neurosurgery
Surgery is the first standard treatment for glioblastoma, that aims to achieve a maximum reduction of tumour volume without affecting the functional outcome of patients.
But even when surgical resection is complete, the invasiveness of glioblastoma and its proliferating nature do not allow a local control with standard therapeutic protocols.
Photodynamic therapy (PDT) opens new possibilities to tackle this challenge and stop tumour growth.